• An in-depth look at the new plans for Gastric Cancer (GC) treatment
  • Atefeh Kamran,1 Ali Rezaeian,2 Zahra Amirkhani,3,*
    1. Medical Student, Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
    2. Medical Student, Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
    3. Assistant Professor, Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran.


  • Introduction: Gastric cancer (GC) is one of the most common malignancies worldwide. Gastric Cancer is caused by an uncontrolled growth of cells that starts in the stomach. GC is a multifactorial disease in which environmental and genetic factors can influence its occurrence and development. Today, almost the only preventive method aimed at early detection of tumors is cancer screening. The first way to diagnose GC is to observe the symptoms of the disease in a person. Vomiting blood, seeing blood in the stool, sudden, severe and unwanted weight loss, indigestion and feeling pain and bloating in the upper abdomen, feeling full early after eating are symptoms of GC. But typically sampling or biopsy is the surest way to detect GC. Endoscopy, blood tests, CT scans, PET scans, tumor marker tests, stool blood tests and breath tests are other ways to diagnose GC. Treatment of GC depends on many factors, but generally a combination of techniques is used. Common treatments include surgery to remove the tumor, chemotherapy to kill cancer cells, compression to kill cancer cells, and targeted molecular treatments to inhibit the growth of cancer cells. Complementary therapies such as radiotherapy and hormone therapy can also be used. The aim of the study was to take an in-depth look at new programs for GC treatment.
  • Methods: The present paper is a review study. In this study,49 articles published from 2018 to2024, which were in the form of quantitative studies, meta-analysis and original research and systematic review were examined. Entry criteria included: Availability of full text and articles published between 2018 and 2024, and exit criteria included: Case Report studies. The MeSH terms were " Gastric cancer " OR " H. Pylori " OR " Hyperthermic Intraperitoneal Chemotherapy (HIPEC)".
  • Results: Most GC are found when the disease has spread beyond the stomach, when a cure is less likely. A new approach to treating GC called hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated liquid chemotherapy directly to the abdomen where it can target the cancer. During a HIPEC treatment, the abdominal cavity is bathed with hot chemotherapy to kill any microscopic cancer cells. The chemo can stay locally in that region, the abdomen, and then it can continue to work even past the procedure. And then that allows us to use really high concentrations of the chemo directly where the cancer is. HIPEC has been used as a treatment for other cancers for several decades, but just recently has been adapted to GC. The outcomes have been significantly better than those achieved with traditional chemotherapy. chemotherapy combined with surgery prolongs the survival of patients with other localized metastases in the future. The development of new treatment strategies, including new chemotherapeutic agents and regimens, could improve the survival outcomes of patients with oligometastatic from gastric cancer.
  • Conclusion: GC is a heterogeneous disease that affects a large number of people annually and remains an unmet clinical problem. GC severely affects the population of developing countries. Improvements in hygiene and eradication of H. Pylori significantly improved these gastric cancer statistics in developing countries. According to our studies gastric cancer accounts for about 6% of cancers worldwide and is the fifth most frequently diagnosed malignant cancer and the third leading cause of cancer-related death. With the development of genomics, the updating of modern imaging technology and the emergence of artificial intelligence and big data, GC surgical treatment has gradually entered medicine. Advances have been made in understanding the pathogenesis and Molecular Biology of gastric cancer and optimizing available treatment options and methods. In the future, however, the focus should be on exploring more gastric cancer classification, fine-tuning treatment strategies and developing new drugs for patients with advanced gastric cancer. As the research progresses, I hope there will be more progress in discovering more effective treatment options to improve the survival statistics of this deadly disease.
  • Keywords: Gastric cancer, H. Pylori, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)